Combined inhibition of IGF-1R and the Src family non-receptor tyrosine kinases leads to an effective suppression of AKT1 and AKT2 activation and consequently to a decreased intratibial tumor growth of prostate cancer cells [143]. The gene discussed is AKT1; the disease is prostate carcinoma.